Local Anesthetics

Epinephrine activates alpha-1 adrenergic receptors on vascular smooth muscle at the injection site, causing vasoconstriction and reducing local blood flow. This produces three benefits that make it a valuable additive to many local anesthetic formulations.

First, slowed systemic absorption prolongs the duration of anesthesia. The local anesthetic remains at the injection site longer when blood flow is reduced, extending the period of effective nerve blockade. This is the most clinically important benefit — a block that might last 60 minutes with lidocaine alone may last 90 to 120 minutes when epinephrine is added.

Second, reduced systemic absorption lowers the peak plasma concentration of the local anesthetic. Lower peak plasma levels mean reduced risk of systemic toxicity affecting the central nervous system and heart. This safety benefit is particularly relevant when large doses are used for major nerve blocks or epidural anesthesia.

Third, epinephrine serves as a marker for unintended intravascular injection. When a small test dose containing epinephrine is injected before the full local anesthetic dose, any sudden increase in heart rate — typically 20 or more beats per minute within 60 seconds — indicates the needle tip is inside a blood vessel. The injection is stopped immediately, preventing the potentially catastrophic consequence of depositing the full local anesthetic dose directly into the circulation.

The standard concentration of epinephrine used as a local anesthetic additive is 1:200,000, which equals 5 micrograms per milliliter. This concentration is sufficient to produce meaningful vasoconstriction without delivering a systemic epinephrine dose large enough to cause cardiovascular effects in most patients. Higher concentrations are occasionally used for specific indications but carry greater risk of cardiovascular side effects.

Epinephrine must not be added to local anesthetic solutions intended for injection into end-artery regions — anatomical areas where a single artery supplies the tissue with no collateral circulation. The fingers, toes, penis, tip of the nose, and ear pinnae are the classic end-artery regions. Vasoconstriction in these areas can reduce blood flow enough to cause ischemia and tissue necrosis. The mnemonic taught widely is "no epinephrine in the fingers, toes, nose, and hose" — a reminder of the end-artery locations.

Epinephrine is also contraindicated in intravenous regional anesthesia (the Bier block technique, described in Section 2), where the risk of systemic epinephrine release when the tourniquet is deflated adds unacceptable cardiovascular risk to an already high-risk situation. Patients with severe coronary artery disease or uncontrolled hypertension represent relative contraindications, where the cardiovascular effects of even small systemically absorbed epinephrine doses warrant caution.

At low epidural concentrations, bupivacaine and ropivacaine block the small pain-transmitting fibers (type C and type A-delta) while leaving the large motor fibers (type A-alpha) largely intact. The patient experiences effective relief from labor pain — the intense visceral pain of uterine contractions — while retaining the ability to move the legs and bear weight. This is the pharmacological basis of what is colloquially called the "walking epidural."

At higher concentrations, the same agents block motor fibers as well, producing the denser sensory and motor block required for surgical anesthesia — for example, during a cesarean section. The drug is the same; the concentration determines the clinical effect.

Ropivacaine is particularly valued for its motor-sparing properties at lower concentrations compared to bupivacaine, making it a preferred agent for labor epidural analgesia where ambulation is desired. Both agents produce equivalent surgical anesthesia at appropriate higher concentrations.

For lidocaine without epinephrine, the approximate maximum dose is 4 to 5 milligrams per kilogram of body weight. With epinephrine added, the limit increases to approximately 7 milligrams per kilogram — the vasoconstriction slows absorption enough to allow a larger total dose without reaching toxic plasma concentrations.

For bupivacaine, the maximum dose is approximately 2 to 3 milligrams per kilogram and does not increase substantially with epinephrine addition. The lower limit for bupivacaine reflects its cardiotoxic potential — at the plasma concentrations that cause toxicity, bupivacaine produces cardiac arrhythmias and cardiac arrest that are notoriously resistant to resuscitation.

The mechanism of systemic local anesthetic toxicity is the same as the mechanism of nerve blockade: sodium channel blockade. When systemic plasma concentrations rise high enough, local anesthetics block sodium channels in the brain and heart just as they block them in peripheral nerves. In the brain, this produces the progression of central nervous system toxicity described in Module 4 — from circumoral numbness and tinnitus through seizures. In the heart, sodium channel blockade slows conduction and depresses myocardial contractility.

The dose limits are not absolute thresholds below which toxicity never occurs — highly vascular injection sites such as intercostal or paracervical blocks produce faster absorption and higher peak plasma levels than subcutaneous infiltration at the same total dose. Clinicians must factor in site of injection, rate of injection, and patient characteristics (reduced hepatic function, low plasma protein binding in pregnancy) when determining safe dosing.